By Fineline Cube 
China-based Boai NKY Medical Holdings Ltd (SHE: 300109) announced that its joint venture company, Beijing Liangyuan Bioscience, LLC has received clinical approval in China for its LYC001, a high affinity complex (HAC) targeting human interleukin-2 (IL-2), for the treatment of advanced solid tumors. This marks a significant milestone in the development of innovative therapies for cancer patients.
LYC001 and HAC Technology
LYC001 is China’s first indigenous and globally pioneering Class 1 biologic developed using the HAC technology platform. The HAC platform represents a world-first lymphatic system-targeted drug delivery technology, addressing key limitations of conventional macromolecular drugs such as low stability and poor targeting due to systemic circulation distribution.
Drug Advantages
As the inaugural product of the HAC platform, LYC001 exhibits a distinct hierarchical structure and enhanced physicochemical stability. This significantly improves the solubility and stability of interleukin-2 (IL-2). Administered subcutaneously, the drug demonstrated over 90% bioavailability in pre-clinical settings. It rapidly induces CD8+ T cell activation and expansion, highlighting its potential as a powerful therapeutic option for advanced solid tumors.-Fineline Info & Tech